Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

F0700000

Furosemide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H11ClN2O5S
CAS Number:
54-31-9
Molecular Weight:
330.74
MDL number:
MFCD00010549
UNSPSC Code:
41116107
PubChem Substance ID:
329799665
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

furosemide

manufacturer/tradename

EDQM

mp

220 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

Gene Information

human ... SLC12A1(6557)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Furosemide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1287008

Furosemide, United States Pharmacopeia (USP) Reference Standard

F0702000

Furosemide impurity A, European Pharmacopoeia (EP) Reference Standard

1287020

Furosemide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1287030

Furosemide Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001493

Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard

BP547

Furosemide, British Pharmacopoeia (BP) Reference Standard

PHR1816

Furosemide Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP074

4-Chloro-5-sulfamoylanthranilic acid, British Pharmacopoeia (BP) Reference Standard

PHR2457

2,4-dichlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Case scenario: Hemodynamic management of postoperative acute kidney injury.
Matthieu Legrand et al.
Anesthesiology, 118(6), 1446-1454 (2013-04-06)
Naoki Sato et al.
Circulation journal : official journal of the Japanese Circulation Society, 77(4), 944-951 (2013-03-19)
Hospitalized heart failure (HHF) is a critical issue in Japan. To improve its management and outcomes, the clinical features, in-hospital management, and outcomes should be analyzed to improve the guidelines for HHF. The acute decompensated heart failure syndromes (ATTEND) registry
Maarten C van Loon et al.
Hearing research, 298, 17-26 (2013-01-31)
It is well known that spiral ganglion cells (SGCs) degenerate in hair-cell-depleted cochleas and that treatment with exogenous neurotrophins can prevent this degeneration. Several studies reported that, in addition, SGC size decreases after deafening and increases after neurotrophic treatment. The
F H Wilson et al.
Science (New York, N.Y.), 293(5532), 1107-1112 (2001-08-11)
Hypertension is a major public health problem of largely unknown cause. Here, we identify two genes causing pseudohypoaldosteronism type II, a Mendelian trait featuring hypertension, increased renal salt reabsorption, and impaired K+ and H+ excretion. Both genes encode members of
Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service